and with a very low Burn-rate of around $1.5 Mil per Quarter...

and with a very low Burn-rate of around $1.5 Mil per Quarter this Company will reach DEEP Profitability very quickly .You Guys should see the Big Picture of this Company to realize the MEGA Potenital here .Patience will payoff big time here .GL



As announced to the ASX on 3 November 2014, the new product suite comprises 23 tablet and capsule products for conditions including Parkinson’s Disease,depression, infection,hypertension and pain. The total current annual global market for these products in these presentations is approximately $460 million (IMS).

In parallel with the integration of these drugs into IDT’s manufacturing facility, the Company is also in discussions with over half a dozen potential commercialisation partners interested in US distribution of the products. Interest has been strong and indicative term sheets have already been received from several of these parties. It is the Company’s expectation that IDT will select one or more commercialisation partners and execute US distribution deal(s) for the initial cohort of products in early to mid 2015.




The Abbreviated New Drug Application (ANDA) submission for Temozolomide is the first of IDT’s generic filings (ASX announcement 18 November 2013). It has now been accepted for
review by the United States Food and Drug Administration (FDA) and is currently progressing through the FDA’s review process.

Temozolomide is indicated for the treatment of melanoma and glioblastoma multiforme and had US sales of approximately USD 340 million in the 12 months ending 31 May 2014 .